The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?
Open Access
- 2 March 2007
- journal article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (7), 978-981
- https://doi.org/10.1007/s00259-007-0387-4
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.2005
- Radiolabelling DOTA-peptides with 68GaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.2005
- (68)Ga-labeled peptides in tumor imaging.2005
- 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5European Journal of Nuclear Medicine and Molecular Imaging, 2004
- PET imaging of GRP receptor expression in prostate cancer.2004
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary dataEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphyInternational Journal of Cancer, 1999